RxDoctor Payments Data

Sean Enkiri, MD

Interventional Cardiology · Littleton, CONPI 1881816064

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $14,406 of the $17,623 with a category attached, or 81.7%. 42 manufacturers reported payments, led by Edwards Lifesciences at 26.1% of the total. 2025 is the largest year on record at $5,433, 2.2 times the $2,449 reported in 2019.

$17,623in general payments, 2019–2025

Across 540 payments — averaging $32.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$5K
  • Medtronic$3K
  • Shockwave Medical, Inc$2K
  • Boston Scientific$2K
  • Abbott$1K
  • Amgen$778
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$4252%
  • Travel & lodging$2,77816%
  • Food & beverage$14,40682%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,623 in reported general payments places this provider in the 70th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$140,616
Medicare patients
409
Services billed
1,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban305$425,608
JardianceEmpagliflozin120$153,864
Repatha SureclickEvolocumab89$98,660
XareltoRivaroxaban56$72,075
EntrestoSacubitril/Valsartan36$45,185
Praluent PenAlirocumab28$30,280
FarxigaDapagliflozin Propanediol16$16,407
Repatha SyringeEvolocumab17$10,874
Rosuvastatin Calcium325$5,772
Ezetimibe182$5,118
Metoprolol Succinate340$4,470
Atorvastatin Calcium436$3,615
Losartan Potassium367$2,916
Lisinopril319$2,529
Amlodipine Besylate358$2,284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$425,608305 claims
Boehringer IngelheimJardiance$175$153,864120 claims
Johnson & JohnsonXarelto$263$72,07556 claims
NovartisEntresto$333$45,18536 claims
AstraZenecaFarxiga$312$16,40716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →